MSKCC has opened a new 72,000-square-foot surgical center that was uniquely designed to take advantage of the latest medical technology while enhancing patient safety and efficiency of care.
MSKCC today announced a major commitment from publisher, real estate developer, and MSKCC Board member Mortimer B. Zuckerman of $100 million from his charitable trust toward Memorial Sloan-Kettering's new cancer research facility, including a 23-story laboratory structure that opened in May.
A new multicenter study is the first to suggest that the prophylactic removal of the ovaries and fallopian tubes may provide a different benefit for women who carry a genetic mutation in the BRCA2 gene than for those who have a BRCA1 genetic mutation.
According to a new study, the drug sunitinib malate (Sutent®) is more effective than the current standard cytokine treatment given as an initial therapy for patients with advanced kidney cancer, also known as metastatic renal cell carcinoma.
A multi-institutional study led by MSKCC suggests a link between childhood chemotherapy and development of a rare type of kidney cancer, illustrating the importance of studying the long-term side effects of cancer treatment, particularly as more people survive the disease.
MSKCC researchers have gained new insight into the mechanism by which a cell copies its genetic material prior to cell division, a process known as DNA replication.
MSKCC experts advise that postmenopausal women who are at high risk for breast cancer and are considering taking raloxifene to prevent the disease should wait for further research and Food and Drug Administration approval before taking raloxifene for this purpose.
Peter Scardino, a urologic surgeon and internationally recognized authority on prostate cancer, has been named the new Chairman of the Department of Surgery at MSKCC.
Physician-scientist Charles Sawyers has been appointed Chairman of MSKCC's new Human Oncology and Pathogenesis Program, which will capitalize on recent advances in understanding cancer cell biology and in the development of molecularly targeted drugs and other rationally based interventions.
Alan Hall, Chairman of the Cell Biology Program in the Sloan-Kettering Institute, has been honored with a 2006 Gairdner International Award, which presents awards annually to recognize and reward outstanding biomedical scientists who have made original contributions to the understanding of human disease.
News@MSKCC provides journalists with news and information from Memorial Sloan-Kettering Cancer Center and is released six times a year.
For more information about these and other potential story ideas, contact Memorial Sloan-Kettering's Department of Public Affairs at: 212-639-3573 or at mediastaff@mskcc.org
